Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.
ApexOnco Front Page
Recent articles
First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
Three private biotechs enter clinical trials, one targeting KRAS.
The company will start three phase 3 trials of its G12D project this year.
But PFS data are lacking, and there are questions about first and second-line plans.
But the company still has a lot to prove with ERAS-0015.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
